Dermata Therapeutics (DRMA) Change in Account Payables (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Change in Account Payables of -$51128.0 for Q1 2026, down 150.09% year-over-year from $102064.0 in Q1 2025, and up 39.11% quarter-over-quarter from -$83967.0 in Q4 2025.
Dermata Therapeutics (DRMA) Change in Account Payables (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$51128.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 150.09% year-over-year to -$51128.0; the TTM figure through Mar 2026 stood at -$541248.0 (down 1561.49% YoY), while the FY2025 annual figure was -$388056.0, down 257.62% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$51128.0, up from -$83967.0 in the prior quarter.
- The five-year high for Change in Account Payables was $403735.0 in Q2 2024, with the low at -$458880.0 in Q2 2025.
- The 5-year median for Change in Account Payables is -$43482.0 (2024), against an average of -$11583.1.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 2921.14% in 2023, then sank 1110.3% in 2024.
- Dermata Therapeutics' Change in Account Payables stood at $12961.0 in 2022, then surged by 2921.14% to $391570.0 in 2023, then sank by 125.08% to -$98188.0 in 2024, then gained by 14.48% to -$83967.0 in 2025, then soared by 39.11% to -$51128.0 in 2026.
- Business Quant data shows DRMA's Change in Account Payables at -$51128.0 in Q1 2026, -$83967.0 in Q4 2025, and $52727.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dermata Therapeutics | 5.40 Mn | 5.40 Mn | - | -51,128.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51,128.00 |
| Mar 31, 2026 | -51,128.00 |
| Dec 31, 2025 | -83,967.00 |
| Dec 31, 2025 | -83,967.00 |
| Sep 30, 2025 | 52,727.00 |
| Sep 30, 2025 | 52,727.00 |
| Jun 30, 2025 | -458,880.00 |
| Jun 30, 2025 | -458,880.00 |
| Mar 31, 2025 | 102,064.00 |
| Mar 31, 2025 | 102,064.00 |
| Dec 31, 2024 | -98,188.00 |
| Dec 31, 2024 | -98,188.00 |
| Sep 30, 2024 | -370,577.00 |
| Sep 30, 2024 | -370,577.00 |
| Jun 30, 2024 | 403,735.00 |
| Jun 30, 2024 | 403,735.00 |
| Mar 31, 2024 | -43,482.00 |
| Mar 31, 2024 | -43,482.00 |
| Dec 31, 2023 | 391,570.00 |
| Dec 31, 2023 | 391,570.00 |